Skip to main content
. Author manuscript; available in PMC: 2011 Feb 10.
Published in final edited form as: Eur J Pharmacol. 2009 Oct 31;627(1-3):156. doi: 10.1016/j.ejphar.2009.10.062

Figure 1.

Figure 1

Chemical structures of GPI-5693 and 2-PMPA. GPI-5693 is the first orally active, thiol-based NAALADase inhibitor tested in humans. 2-PMPA is the first prototype phosphonate-based NAALADase inhibitor and has been extensively used in animal models studying the physiological role of NAALADase inhibition and possible therapeutic benefits. * Racemization site.